Ritter's technology platform is based upon gastrointestinal physiology, metabolism and gut adaptation. Current focus is on developing a long-term therapy for lactose intolerance.

Product development is supported by a medical advisory team comprised of advanced scientists and researchers in the fields of gastroenterology, biotechnology, pharmacology, clinical laboratory medicine and nutritional sciences.

Future product development will focus on digestive diseases, including irritable bowel syndrome (IBS), Crohn's disease and ulcerative colitis.